BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharmaconomics//FDA Catalyst Calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
BEGIN:VEVENT
UID:pharmaconomics-560@pharmaconomics
DTSTAMP:20260707T020619Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:PVLA PDUFA — QTORIN™ rapamycin (estimated date)
DESCRIPTION:The FDA's approval decision on QTORIN™ rapamycin for microcystic lymphatic malformations is due ~ Dec 31\, 2026. A green light opens the market\; a complete response letter (CRL) usually sinks the stock.\n\nPrimary source: https://www.sec.gov/Archives/edgar/data/1583648/000119312526210605/pvla-ex99_1.htm\n\nTrack it: https://pharmaconomics.com/e/560
URL:https://pharmaconomics.com/e/560
TRANSP:TRANSPARENT
BEGIN:VALARM
TRIGGER:-P1D
ACTION:DISPLAY
DESCRIPTION:PVLA catalyst tomorrow
END:VALARM
END:VEVENT
END:VCALENDAR